Document:USA 21 CFR Part 809 06-May-2024: Difference between revisions
From GxPlex
Gxplex admin (talk | contribs) m 1 revision imported |
gxplex>GxPlexBot Import from GxPlex Excel |
(No difference)
| |
Revision as of 15:27, 29 June 2026
| Document information | |
|---|---|
| Reference | USA 21 CFR Part 809 06-May-2024 |
| Validity area | USA |
| Scope(s) | G |
| Document name | 21 CFR Part 809 |
| Version / Revision | 06-May-2024 |
| Status | Current |
| Document type | Legal act |
| Language(s) | EN |
| Description | |
| Official source | — |
| Restricted access | No |
| Submitted by | Florian Adragna |
| Contributors | |
References
| Reference | Scope | Document part | Language | Preview |
|---|---|---|---|---|
| Reference:USA 21 CFR Part 809 06-May-2024 § 809.3 (a) | G | § 809.3
(a) || EN || § 809.3 Definitions. (a) In vitro diagnostic products are those reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including a determination of the ... |
